Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2873 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Azeria Therapeutics–SEVERAL: investment, 201911 financing round Series B £32m led by Syncona with £29.5m plus investor CRT Pioneer Fund 2019-11-21
Azeria Therapeutics–Sixth Element Capital: investment, 201911 financing round Series B totalling £32m incl existing + co-investor CRT Pioneer Fund 2019-11-21
Azeria Therapeutics–Syncona: investment, 201911 financing round Series B totalling £32m incl £29.5m from new + lead investor Syncona 2019-11-21
Turbine–Atlantic Labs: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Atlantic Labs Manager GmbH 2019-11-13
Turbine–Delin Ventures: investment, 201911 first institutional financing round totalling €3m incl lead investor Delin Ventures 2019-11-13
Turbine–o2h: investment, 201911 first institutional financing round totalling €3m incl new + co-investor o2h Ventures 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Esther Dyson 2019-11-13
Turbine–PERSON: investment, 201911 first institutional financing round totalling €3m incl existing + co-investor Vishal Gulati 2019-11-13
Turbine–SEVERAL: investment, 201911 first institutional financing round €3m led by Delin Ventures + incl Atlantic Labs et al. 2019-11-13
Turbine–Zyme Communications: public relations, 201911 service existent by Zyme 2019-11-13
Expedeon–Abcam: investment, 201911– acquisition €120m cash of immunology + proteomics business of Expedeon by Abcam ANNOUNCED 2019-11-11
Owlstone–Thermo Fisher: mass spectrometry, 201911– collab integration of Q Exactive GC Hybrid Quad-Orbitrap MS into Breath Biopsy platform 2019-11-07
Artios Pharma–Univ Texas: ATR inhibitors, 201911– license excl ww to small-molecula ATR inhibitor programme from MD Anderson + ShangPharma Innovation 2019-11-06
Ervaxx–Huntsworth: public relations, 201911 service existent by Citigate Dewe Rogerson 2019-11-06
Greenough–KDM Communications: investment, 201911 merger combination to provide transatlantic PR services 2019-11-06
OTHER–Ervaxx: cancer immunotherapy, 201911 collab existent strategic r+d partnership with undisclosed leading global pharma company 2019-11-06
Rentschler–General Electric: single-use bioreactor, 201911–202006 supply Xcellerex XDR-500 bioreactor for Rentschler facility in Milford, MA 2019-11-06
Urania Therapeutics–Andrew Lloyd Associates: public relations, 201911 service existent by ALA 2019-11-06
Pieris–BVF Partners: investment, 201911 private placement totalling $32m incl existing + lead investor BVF Partners 2019-11-04
Pieris–SEVERAL: investment, 201911 private placement $32m w 9.015m units (shares + warrants) at $3.55/unit led by BVF Partners 2019-11-04
AstraZeneca–BBG/Braun Group: quetiapine fumarate, 201910– acquisition $178m upfront + up to $61m rights to Seroquel/XR in Europe + RU by Cheplapharm 2019-10-30
Bavarian Nordic–GSK: vaccines, 201910 acquisition up to €796m incl €301m upfront of manufacturing + global rights to Rabipur/RabAvert + Encepur by BN 2019-10-21
Danaher–Sartorius: investment, 201910– acquisition $750m three life science businesses by Sartorius part of regulatory clearance for GE/Danaher deal 2019-10-21
Sofinnova–SEVERAL: investment, 201910 closing €333m of Sofinnova Capital IX fund 2019-10-17
Adaptate Biotherapeutics–Abingworth: investment, 201910 investment by Abingworth + Takeda facilitating spin-out of Adaptate from GammaDelta Tx 2019-10-16
Adaptate Biotherapeutics–SEVERAL: investment, 201910 spin-out from GammaDelta Therapeutics with investment from Abingworth & Takeda Pharmaceutical 2019-10-16
Adaptate Biotherapeutics–Takeda: investment, 201910 investment by Abingworth + Takeda with time-limited option to acquire Adatpate for Takeda 2019-10-16
Healx–Amadeus Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Amadeus Capital Partners 2019-10-16
Healx–Atomico: investment, 201910 financing round Series B totalling $56m incl new + lead investor Atomico 2019-10-16
Healx–Balderton Capital: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Balderton Capital 2019-10-16
Healx–btov Partners: investment, 201910 financing round Series B totalling $56m incl new + co-investor btov Partners 2019-10-16
Healx–Global Brain: investment, 201910 financing round Series B totalling $56m incl new + co-investor Global Brain 2019-10-16
Healx–Intel: investment, 201910 financing round Series B totalling $56m incl new + co-investor Intel Capital 2019-10-16
Healx–PERSON: investment, 201910 financing round Series B totalling $56m incl exisiting + co-investor Jonathan Milner 2019-10-16
Healx–SEVERAL: investment, 201910 financing round Series B $56m led by new investor Atomico 2019-10-16
Mogrify–24Haymarket: investment, 201910 financing round Series A first closing totalling $16m incl existing + co-investor 24Haymarket 2019-10-14
Mogrify–Ahren Innovation Capital: investment, 201910 financing round Series A first closing totalling $16m incl existing + lead investor Ahren 2019-10-14
Mogrify–Parkwalk Advisors: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Parkwalk 2019-10-14
Mogrify–SEVERAL: investment, 201910 financing round Series A first closing $16m led by existing investor Ahren Innovation Capital 2019-10-14
Mogrify–Univ Bristol: investment, 201910 financing round Series A first closing totalling $16m incl new + co-investor Univ Bristol Enterprise Fund III 2019-10-14
Biocon–Evotec: biosimilars, 201910– license €na to Biocon Biologics for pre-clinical biosimilar asset of Just-Evotec Biologics 2019-10-10
D.I. Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Korea by D.I. Biotech Ltd 2019-10-09
Imperial Life Sciences–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in India by Imperial 2019-10-09
Kiko Tech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Japan by Kiko Tech Co Ltd 2019-10-09
N-Side–Sciad Communications: public relations, 201910 service existent by Sciad 2019-10-09
Optec (RU)–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Russia by Optec LLC 2019-10-09
Trio Biotech–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in China by Trio Biotech Co Ltd 2019-10-09
Unimed Healthcare–Solentim: laboratory equipment, 201910 distribution existent of Solentim’s cell line developm instruments in Taiwan by Unimed 2019-10-09
GSK–Lyell Immunopharma: cancer cell therapy, 201910–202409 collab 5y developm of technologies to improve cancer cell therapies 2019-10-08
Merck (US)–4D Pharma: microbiomic treatments, 201910– collab r+d Live Biotherapeutics as vaccines 2019-10-08
MiroBio–Advent Venture Partners: investment, 201910 financing round Series A totalling £27m incl co-investor Advent Life Sciences 2019-10-07
MiroBio–GSK: investment, 201910 financing round Series A totalling £27m incl co-investor SR One 2019-10-07
MiroBio–Samsara Biocapital: investment, 201910 financing round Series A totalling £27m incl co-lead investor Samsara Biocapital 2019-10-07
MiroBio–SEVERAL: investment, 201910 financing round Series A £27m co-led by Oxford Sciences Innovation + Samsara Biocapital 2019-10-07
MiroBio–Univ Oxford: investment, 201910 financing round Series A totalling £27m incl co-lead investor Oxford Sciences Innovation 2019-10-07
Congenica–Genomenon: genomic software tools, 201910– collab integration of Mastermind Genomic Search Engine into clinical decision support s/w 2019-10-02
AstraZeneca–N-Side: clinical supply chain management s/w, 201910– supply implementation of cloud-based N-Side Suite for Clincial Trials 2019-10-01
Novartis–Microsoft: artificial intelligence, 201910– collab strategic multiyear AI for drug r+d + commercialisation 2019-10-01
Arctoris–SEVERAL: investment, 201909 seed financing round £3.2m led by RT Partners 2019-09-30
STipe Therapeutics–SEVERAL: investment, 201909 financing round Series A €20m co-led by Arix Bioscience + Novo Holdings 2019-09-30
MolPort–Alto Marketing: public relations, 201909 service existent by Alto Marketing Ltd 2019-09-24
Oncimmune–IPF Partners: credit, 201909– 202309 credit facility €8.5m four year incl warrant for 2m new ordinary shares IPF Management SA 2019-09-20
BenevolentAI–Temasek: investment, 201909 investment $90m from Tesmasek 2019-09-17
Life Healthcare Group–AC Immune: PET tracer, 201909 collab existent developm Tau PET tracer PI-2620 with Life Molecular Imaging 2019-09-17
Autolus–PPF Group: investment, 201909 acquisition 19.2% stake in market through Nasdaq by PPF Group NV 2019-09-16
Avalon Ventures–GSK: investment, 201909 acquisition of Sitari Pharmaceuticals incubated 11/13 as part of GSK/Avalon collaboration 2019-09-11
Cedilla Therpapeutics–o2h: drug discovery services, 201909– collab expansion synthetic chemistry services for small molecules for protein regulation 2019-09-11
4BIO Ventures–SEVERAL: investment, 201909 first closing $50m of 4BIO Ventures II fund targeting $150m 2019-09-09
BioNTech–SEVERAL: investment, 201909–201910 US IPO $150m+$22.5m with 10m+1.5mADSs at $15/ADS at Nasdaq Global Select Market 2019-09-09
Lightcast Discovery–Instinctif Partners: public relations, 201909 service existent by Instinctif 2019-09-09
Lightcast Discovery–SEVERAL: investment, 201909 seed financing round £1.3m ($1.6m) from private investors 2019-09-09
iStar Medical–Optimum Strategic Communications: public relations, 201909 service existent by Optimum 2019-09-05
Theragnostics–AstraZeneca: PARP inhibitors, 201909– license ww freedom to operate for developm of rPARPi as cancer theragnostic 2019-09-05
Theragnostics–Optimum Strategic Communications: public relations, 201909 service existent by Optimum 2019-09-05
Azeria Therapeutics–Sixth Element Capital: investment, 201809 Series A investment £5.5m from CRT Pioneer Fund 2019-09-04
Achilles Therapeutics–Forbion: investment, 201909 financing round Series B totalling £100m incl new + co-investor Forbion 2019-09-03
Achilles Therapeutics–Invus Group: investment, 201909 financing round Series B totalling £100m incl new + co-investor Invus 2019-09-03
Achilles Therapeutics–Perceptive Advisors: investment, 201909 financing round Series B totalling £100m incl new + co-investor Perceptive Advisors 2019-09-03
Achilles Therapeutics–RA Capital Management: investment, 201909 financing round Series B totalling £100m incl new + lead investor RA Capital 2019-09-03
Achilles Therapeutics–Redmile Group: investment, 201909 financing round Series B totalling £100m incl new + co-investor Redmile Group 2019-09-03
Achilles Therapeutics–SEVERAL: investment, 201909 financing round Series B £100m led by RA Capital Management 2019-09-03
Achilles Therapeutics–Syncona: investment, 201909 financing round Series B totalling £100m incl existing + co-investor Syncona 2019-09-03
Univ College London–Bruker Corp: atomic force microscope, 201908 supply existent London Centre for Nanotechnology long-term user of NanoWizard systems 2019-09-02
Kinomica–BioCity (GB): investment, 201908 investment by BioCity via Innovate UK Precision Medicine Investment Accelerator 2019-08-29
Protelux (RU)–Unibio: protein production from methane, 201908 collab existing buidling + operating plant for Uniprotein production in Russia 2019-08-28
Unibio–SEVERAL: investment, 201908 financing round $15m (£12.4m) from existing + new shareholders led by West Hill Capital 2019-08-28
Unibio–West Hill Capital: investment, 201908 financing round totalling $15m (£12.4m) incl lead investor West Hill Capital 2019-08-28
Adaptimmune–Noile-Immune: T cell therapy, 201908– collab up to $312m + royalties developm of SPEAR T-cell products using PRIME technology 2019-08-27
Vaccitech–Scius Communications: public relations, 201908 supply service existent by Scius Communications 2019-08-27
AstraZeneca–FibroGen: roxadustat, 201908 collab existent commercialisation of roxadustat in China by AstraZeneca 2019-08-22
Juvenescence–SEVERAL: investment, 201908 financing round Series B $100m incl founders + private investment companies 2019-08-19
AstronauTx–United Kingdom (govt): investment, 201908 investment £6.5m from Dementia Discovery Fund 2019-08-13
Synpromics–AskBio: investment, 201908 acquisition of Synpromics Ltd by Asklepios Biopharmaceutical Inc 2019-08-13
Cavion–Jazz Pharmaceuticals: investment, 201908 acquisition $52.5m upfront + $260m milestones of Cavion Inc by Jazz 2019-08-12
MeiraGTx–SEVERAL: investment, 201908 public offering $75.2m+$11.28m with 3.2m+480k ordinary shares at $23.5/share 2019-08-07
Imcyse–Andrew Lloyd Associates: public relations, 201908 service existent by ALA 2019-08-05
Atlantic Healthcare–Consilium: public relations, 201907 service existent European IR + media relations by CSC 2019-07-31
Atlantic Healthcare–Lazar Partners: public relations, 201907 service existent US IR + media relations by Lazar Partners 2019-07-31
Wellington Partners–Consilium: public relations, 201907 service existent by CSC 2019-07-31
PredictImmune–BGF (GB): investment, 201907 financing round Series B totalling £10m incl new investor BGF 2019-07-30
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29  next pagenext page



Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top